Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 15/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 5/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757893 | 1.00 | MCL1 (0.38) | MCL1UCHL1HTR3EHTR3BHTR3A | |
| SCHEMBL8275838 | 0.93 | P2RX3 (0.36) | MCL1UCHL1HTR3EHTR3BHTR3A | |
| SCHEMBL13201738 | 0.85 | UCHL1 (0.37) | MCL1UCHL1HTR3EHTR3BHTR3A | |
| SCHEMBL13757884 | 0.83 | AAK1 (0.35) | MCL1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8275831 | 0.82 | CTSB (0.40) | MCL1P2RX3BCL2BCL2L1 | |
| SCHEMBL8271673 | 0.81 | HCRTR1 (0.36) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL15483740 | 0.81 | HTR3E (0.38) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL8275848 | 0.78 | HCRTR1 (0.30) | HCRTR1HCRTR2 | |
| SCHEMBL13385202 | 0.78 | HCRTR1 (0.30) | HCRTR1HCRTR2 | |
| SCHEMBL14092831 | 0.77 | P2RX3 (0.41) | MCL1UCHL1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | MCL1 995/4885UCHL1 2864/4885HTR3E 3762/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MCL1 995/4885UCHL1 2864/4885HTR3E 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.